159139-35-2

Upstream product

• 176107-23-6 4-Isopropyl-3-methanesulfonyl-benzoic acid methyl ester 
• 536-66-3 p-isopropylbenzoic acid 
• 79-08-3 bromoacetic acid 
• 59815-29-1 3-(chlorosulfonyl)-4-isopropylbenzoic acid 
• 74-83-9 methyl bromide 
• 159139-34-1 2-Isopropyl-5-carboxybenzenesulfinic acid 
• 154117-61-0 methyl 3-methylsulfonyl-4-bromobenzoate 

Downstream Products

• 167764-63-8 3-Methylsulfonyl-4-i-propylbenzoyl Chloride 
• 159138-80-4 cariporide 

Relevant academic research and scientific papers

COMPOUNDS FORTREATMENT OF CARDIOVASCULAR DISEASES

Pharmaceutical compositions containing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors in combination with Ca 2+ overload inhibitors, and the use of such combination inhibitors to treat, for example, cardiovascular disease, such as ischemia, particularly, perioperative myocardial ischemic injury in mammals, including humans, are disclosed.

Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity

Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6

Substituted isoquinoline derivatives and their use as anticonvulsivants

This invention relates to novel substituted isoquinoline derivatives and their use as anticonvulsants.

Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith

Benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them. The invention relates to benzoylguanidines of the formula I STR1 where R(1) or R(2) is R(3)-S(O)n -- or R(4)R(5)N--O2 S-- and

Synthesis of the highly selective Na+/H+ exchange inhibitors cariporide mesilate and (3-methanesulfonyl-4-piperidino-benzoyl) guanidine methanesulfonate

The syntheses of cariporide mesilate ((4-isopropyl-3-methanesulfonyl-benzoyl) guanidine methanesulfonate, HOE 642, CAS 159138-81-5), currently being clinically investigated as a protective drug in cardiac ischemia and reperfusion states, and of HOE 694 ((3-methanesulfonyl-4-piperidino-benzoyl)guanidine methanesulfonate, CAS 149725-40-6), widely used as a physiological and pharmacological research tool in studies comprising Na+/H+ exchange (NHE) inhibition, are described. Additionally, their selectivity on the different subtypes is disclosed.